Home
About
Overview
Sharing Data
ORCID
Help
History (1)
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908.
View in:
PubMed
subject areas
Adult
Aged
Carcinoma, Non-Small-Cell Lung
Central Nervous System Neoplasms
Disease-Free Survival
Drug Resistance, Neoplasm
Female
Gene Expression Regulation, Neoplastic
Humans
Male
Middle Aged
Mutation
Neoplasm Proteins
Oncogene Proteins, Fusion
Organophosphorus Compounds
Pyrazoles
Pyridines
Pyrimidines
Receptor Protein-Tyrosine Kinases
authors with profiles
Ravi Salgia